| Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation UM Zanger, M Schwab Pharmacology & therapeutics 138 (1), 103-141, 2013 | 4061 | 2013 |
| Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry UM Zanger, S Raimundo, M Eichelbaum Naunyn-Schmiedeberg's archives of pharmacology 369, 23-37, 2004 | 1117 | 2004 |
| Characterization of the common genetic defect in humans deficient in debrisoquine metabolism FJ Gonzalez, RC Skodat, S Kimura, M Umeno, UM Zanger, DW Nebert, ... Nature 331 (6155), 442-446, 1988 | 912 | 1988 |
| The genetic determinants of the CYP3A5 polymorphism E Hustert, M Haberl, O Burk, R Wolbold, YQ He, K Klein, AC Nuessler, ... Pharmacogenetics and Genomics 11 (9), 773-779, 2001 | 836 | 2001 |
| Molecular mechanisms of genetic polymorphisms of drug metabolism UA Meyer, UM Zanger Annual review of pharmacology and toxicology 37 (1), 269-296, 1997 | 761 | 1997 |
| Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation UM Zanger, M Turpeinen, K Klein, M Schwab Analytical and bioanalytical chemistry 392, 1093-1108, 2008 | 739 | 2008 |
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver T Lang, K Klein, J Fischer, AK Nüssler, P Neuhaus, U Hofmann, ... Pharmacogenetics and Genomics 11 (5), 399-415, 2001 | 708 | 2001 |
| Sex is a major determinant of CYP3A4 expression in human liver R Wolbold, K Klein, O Burk, AK Nüssler, P Neuhaus, M Eichelbaum, ... Hepatology 38 (4), 978-988, 2003 | 613 | 2003 |
| Nomenclature for human CYP2D6 alleles AK Daly, J Brockmoller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ... Pharmacogenetics and Genomics 6 (3), 193-201, 1996 | 605 | 1996 |
| Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes W Schroth, L Antoniadou, P Fritz, M Schwab, T Muerdter, UM Zanger, ... Journal of Clinical Oncology 25 (33), 5187-5193, 2007 | 594 | 2007 |
| Comprehensive analysis of thiopurine S-methyltransferase phenotype–genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants E Schaeffeler, C Fischer, D Brockmeier, D Wernet, K Moerike, ... Pharmacogenetics and Genomics 14 (7), 407-417, 2004 | 523 | 2004 |
| Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group M Schwab, UM Zanger, C Marx, E Schaeffeler, K Klein, J Dippon, R Kerb, ... Journal of clinical oncology 26 (13), 2131-2138, 2008 | 472 | 2008 |
| Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver AT Nies, H Koepsell, S Winter, O Burk, K Klein, R Kerb, UM Zanger, ... Hepatology 50 (4), 1227-1240, 2009 | 441 | 2009 |
| Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis M Schwab, E Schaeffeler, C Marx, MF Fromm, B Kaskas, J Metzler, ... Gastroenterology 124 (1), 26-33, 2003 | 435 | 2003 |
| Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population EU Griese, UM Zanger, U Brudermanns, A Gaedigk, G Mikus, K Mörike, ... Pharmacogenetics and Genomics 8 (1), 15-26, 1998 | 419 | 1998 |
| Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA I Koch, R Weil, R Wolbold, J Brockmöller, E Hustert, O Burk, A Nuessler, ... Drug Metabolism and Disposition 30 (10), 1108-1114, 2002 | 416 | 2002 |
| Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta … D Meulendijks, LM Henricks, GS Sonke, MJ Deenen, TK Froehlich, ... The Lancet Oncology 16 (16), 1639-1650, 2015 | 377 | 2015 |
| Frequency of C3435T polymorphism of MDR1 gene in African people E Schaeffeler, M Eichelbaum, U Brinkmann, A Penger, S Asante-Poku, ... The Lancet 358 (9279), 383-384, 2001 | 367 | 2001 |
| Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6 UM Zanger, J Fischer, S Raimundo, T Stüven, BO Evert, M Schwab, ... Pharmacogenetics and Genomics 11 (7), 573-585, 2001 | 346 | 2001 |
| Identification and functional characterization of eight CYP3A4 protein variants R Eiselt, TL Domanski, A Zibat, R Mueller, E Presecan-Siedel, E Hustert, ... Pharmacogenetics and Genomics 11 (5), 447-458, 2001 | 340 | 2001 |
